Dyadic International (NASDAQ:DYAI) Stock Price Passes Below Two Hundred Day Moving Average – Here’s Why

Dyadic International, Inc. (NASDAQ:DYAI) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.41 and traded as low as $1.38. Dyadic International shares last traded at $1.49, with a volume of 58,254 shares.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Dyadic International in a report on Thursday, November 14th.

Dyadic International Stock Down 8.6 %

The company has a market cap of $44.09 million, a P/E ratio of -6.48 and a beta of 0.89. The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 1.54. The firm has a fifty day moving average price of $1.33 and a 200 day moving average price of $1.41.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.06. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. The firm had revenue of $1.96 million for the quarter, compared to analyst estimates of $1.05 million. During the same quarter in the prior year, the firm earned ($0.06) EPS. Equities research analysts forecast that Dyadic International, Inc. will post -0.18 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Dyadic International stock. Chapin Davis Inc. grew its position in Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 868,301 shares of the biotechnology company’s stock after buying an additional 21,000 shares during the period. Chapin Davis Inc. owned 2.97% of Dyadic International worth $903,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.